The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
accepted:
26
09
2022
pubmed:
9
10
2022
medline:
2
11
2022
entrez:
8
10
2022
Statut:
ppublish
Résumé
The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in patients with chronic coronary artery disease. The potential effect of years-long exposure to colchicine on renal or liver function and creatine kinase (CK) has not been systematically evaluated and was investigated in this LoDoCo2 substudy. Blood samples drawn from 1776 participants at the close-out visit of the LoDoCo2 trial were used to measure markers of renal function (creatinine, blood urea nitrogen [BUN]), liver function (alanine aminotransferase [ALT], γ-glutamyl transferase [GGT], bilirubin and albumin), and CK. Renal and liver function as well as hyperCKemia (elevated CK) were categorized to the degree of elevation biomarkers as mild, mild/moderate, moderate/severe, and marked elevations. In total, 1776 participants (mean age 66.5 years, 72% male) contributed to this analysis, with a median exposure to trial medication of 32.7 months. Compared with placebo, colchicine was not associated with changes in creatinine and BUN but was associated with elevations in ALT (30 U/L vs. 26 U/L; p < 0.01) and CK (123 U/L vs. 110 U/L; p < 0.01). Most elevations in ALT and CK were mild in both treatment groups. There were no moderate to marked ALT elevations (> 5-10 × upper limit of normal [ULN]) in both treatment groups, and 6 (0.7%) colchicine-treated vs. 2 (0.2%) placebo-treated participants had moderate to marked CK elevations (> 5-10 × ULN). In chronic coronary artery disease, 2-4 years of exposure to colchicine 0.5 mg once daily was associated with small elevations in ALT and CK, but was not associated with changes in renal function. https://www.anzctr.org.au ; ACTRN12614000093684, 24 January 2014.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in patients with chronic coronary artery disease. The potential effect of years-long exposure to colchicine on renal or liver function and creatine kinase (CK) has not been systematically evaluated and was investigated in this LoDoCo2 substudy.
METHODS
METHODS
Blood samples drawn from 1776 participants at the close-out visit of the LoDoCo2 trial were used to measure markers of renal function (creatinine, blood urea nitrogen [BUN]), liver function (alanine aminotransferase [ALT], γ-glutamyl transferase [GGT], bilirubin and albumin), and CK. Renal and liver function as well as hyperCKemia (elevated CK) were categorized to the degree of elevation biomarkers as mild, mild/moderate, moderate/severe, and marked elevations.
RESULTS
RESULTS
In total, 1776 participants (mean age 66.5 years, 72% male) contributed to this analysis, with a median exposure to trial medication of 32.7 months. Compared with placebo, colchicine was not associated with changes in creatinine and BUN but was associated with elevations in ALT (30 U/L vs. 26 U/L; p < 0.01) and CK (123 U/L vs. 110 U/L; p < 0.01). Most elevations in ALT and CK were mild in both treatment groups. There were no moderate to marked ALT elevations (> 5-10 × upper limit of normal [ULN]) in both treatment groups, and 6 (0.7%) colchicine-treated vs. 2 (0.2%) placebo-treated participants had moderate to marked CK elevations (> 5-10 × ULN).
CONCLUSION
CONCLUSIONS
In chronic coronary artery disease, 2-4 years of exposure to colchicine 0.5 mg once daily was associated with small elevations in ALT and CK, but was not associated with changes in renal function.
TRIAL REGISTRATION
BACKGROUND
https://www.anzctr.org.au ; ACTRN12614000093684, 24 January 2014.
Identifiants
pubmed: 36208364
doi: 10.1007/s40261-022-01209-8
pii: 10.1007/s40261-022-01209-8
pmc: PMC9617827
doi:
Substances chimiques
Biomarkers
0
Colchicine
SML2Y3J35T
Creatine Kinase
EC 2.7.3.2
Creatinine
AYI8EX34EU
Banques de données
ANZCTR
['ACTRN12614000093684']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
977-985Informations de copyright
© 2022. The Author(s).
Références
Nidorf SM, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10. https://doi.org/10.1016/j.jacc.2012.10.027 .
doi: 10.1016/j.jacc.2012.10.027
pubmed: 23265346
Nidorf SM, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47. https://doi.org/10.1056/NEJMoa2021372 .
doi: 10.1056/NEJMoa2021372
pubmed: 32865380
Tardif JC, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505. https://doi.org/10.1056/NEJMoa1912388 .
doi: 10.1056/NEJMoa1912388
pubmed: 31733140
Tong DC, et al. Colchicine in patients with acute coronary syndrome: two-year follow-up of the Australian COPS randomized clinical trial. Circulation. 2021;144(19):1584–6. https://doi.org/10.1161/CIRCULATIONAHA.121.054610 .
doi: 10.1161/CIRCULATIONAHA.121.054610
pubmed: 34748393
Visseren FLJ, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. https://doi.org/10.1093/eurheartj/ehab484 .
doi: 10.1093/eurheartj/ehab484
pubmed: 34458905
Ponte-Negretti CI, et al. Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Arch Cardiol Mex. 2022;92(1):99–112. https://doi.org/10.24875/ACM.21000005 .
doi: 10.24875/ACM.21000005
pubmed: 34187049
Health Canada. Product information from Health Canad.a PMS-COLCHICINE E.R Approved 2021-09-10. Available at: https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=100936 . Accessed 6 Jan 2022.
Nidorf SM, et al. The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46–56. https://doi.org/10.1016/j.ahj.2019.09.011 .
doi: 10.1016/j.ahj.2019.09.011
pubmed: 31706144
Kellum JA, et al. Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012. 2021;2(1):1–138.
Ge P-L, Du S-D, Mao Y-L. Advances in preoperative assessment of liver function. HBPD INT. 2014;13(4):361–70. https://doi.org/10.1016/s1499-3872(14)60267-8 .
doi: 10.1016/s1499-3872(14)60267-8
pubmed: 25100120
Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367–79. https://doi.org/10.1503/cmaj.1040752 .
doi: 10.1503/cmaj.1040752
pubmed: 15684121
pmcid: 545762
Levick C. How to interpret liver function tests. SSMJ. 2017;10(2):40–3.
Malakouti M, et al. Elevated liver enzymes in asymptomatic patients—what should i do? J Clin Transl Hepatol. 2017;5(4):394–403. https://doi.org/10.14218/JCTH.2017.00027 .
doi: 10.14218/JCTH.2017.00027
pubmed: 29226106
pmcid: 5719197
Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. Intern Emerg Med. 2012;7(Suppl 3):S193–9. https://doi.org/10.1007/s11739-012-0802-0 .
doi: 10.1007/s11739-012-0802-0
pubmed: 23073857
Janssen L, et al. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev. 2020;100(2):633–72. https://doi.org/10.1152/physrev.00002.2019 .
doi: 10.1152/physrev.00002.2019
pubmed: 31751166
Kyriakides T, et al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010;17(6):767–73. https://doi.org/10.1111/j.1468-1331.2010.03012.x .
doi: 10.1111/j.1468-1331.2010.03012.x
pubmed: 20402744
Robinson PC, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32–8. https://doi.org/10.1016/j.amjmed.2021.07.025 .
doi: 10.1016/j.amjmed.2021.07.025
pubmed: 34416165
Kim HW, et al. Colchicine use and the risk of CKD progression: a multicenter nested case-control study. Rheumatology (Oxford). doi: https://doi.org/10.1093/rheumatology/keac077 . (Epub 9 Feb 2022).
The renal drug reference guide, 1st edn. Adelaide: Kidney Health Australia; 2007.
Oner A, et al. Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol. 2003;18(6):521–6. https://doi.org/10.1007/s00467-003-1129-x .
doi: 10.1007/s00467-003-1129-x
pubmed: 12698329
Imazio M, Brucato A, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;4(7):409–14. https://doi.org/10.7326/0003-4819-155-7-201110040-00359 .
doi: 10.7326/0003-4819-155-7-201110040-00359
Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. https://doi.org/10.1038/ajg.2016.517 .
doi: 10.1038/ajg.2016.517
pubmed: 27995906
Zamor PJ, Russo MW. Liver function tests and statins. Curr Opin Cardiol. 2011;26(4):338–41. https://doi.org/10.1097/HCO.0b013e328347036f .
doi: 10.1097/HCO.0b013e328347036f
pubmed: 21499089
Abbott CE, Xu R, Sigal SH. Colchicine-induced hepatotoxicity. ACG Case Rep J. 2017;4: e120. https://doi.org/10.14309/crj.2017.120 .
doi: 10.14309/crj.2017.120
pubmed: 29201931
pmcid: 5703762
Stewart S, et al. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28. https://doi.org/10.1186/s13075-020-2120-7 .
doi: 10.1186/s13075-020-2120-7
pubmed: 32054504
pmcid: 7020579
Wiggins BS, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95. https://doi.org/10.1161/CIR.0000000000000456 .
doi: 10.1161/CIR.0000000000000456
pubmed: 27754879
Reijneveld JC, et al. Benign prognosis in idiopathic hyper-CK-emia. Muscle Nerve. 2000;23(4):575–9. https://doi.org/10.1002/(sici)1097-4598(200004)23:4%3c575::aid-mus17%3e3.0.co;2-5 .
doi: 10.1002/(sici)1097-4598(200004)23:4<575::aid-mus17>3.0.co;2-5
pubmed: 10716769
Brewster LM, et al. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J. 2007;154(4):655–61. https://doi.org/10.1016/j.ahj.2007.06.008 .
doi: 10.1016/j.ahj.2007.06.008
pubmed: 17892987
Fernandez-Cuadros ME, et al. Colchicine-induced rhabdomyolysis: clinical, biochemical, and neurophysiological features and review of the literature. Clin Med Insights Arthritis Musculoskelet Disord. 2019;12:1179544119849883. https://doi.org/10.1177/1179544119849883 .
doi: 10.1177/1179544119849883
pubmed: 31244525
pmcid: 6580718
Kontos HA. Myopathy associated with chronic colchicine toxicity. N Engl J Med. 1962;266:38–9. https://doi.org/10.1056/NEJM196201042660111 .
doi: 10.1056/NEJM196201042660111
pubmed: 14458279